His departure comes at a time of many concerns within the agency, including staff frustrations with the direction of inspections under new FDA Commissioner Dr Marty Makary. HealthDay News — The ...

Some staff members say they are frustrated with the direction of inspections under new FDA Commissioner Dr Marty Makary. HealthDay News — The official in charge of federal food and drug safety ...

Michael Rogers, associate commissioner for inspections and investigations at the U.S. Food and Drug Administration (FDA), announced his decision Monday in an email to colleagues. "I have decided ...

The official in charge of federal food and drug safety inspections will retire May 14. Michael Rogers, associate commissioner for inspections and investigations at the U.S. Food and Drug ...

The FDA is stepping up its unannounced inspections of foreign manufacturing facilities. In a statement about the increase in inspections, the Food and Drug Administration did not report how many ...

His departure comes as staffers raise concerns about inspection changes Current and former staff say the moves could make inspections less effective WEDNESDAY, May 7, 2025 (HealthDay News) — The ...

Makary wrote in a release. The FDA says its intent will be to expand the surprise inspections at non-U.S. manufacturers that produce items such as food products or essential "medical products." ...

FDA conducts 12K domestic inspections yearly, but only 3K abroad—foreign sites flagged for serious issues over twice as often. Johnson & Johnson, Roche, and Novartis plan over $128 billion in ...

That ends today. This is a key step for the FDA as part of a broader strategy to get foreign inspections back on track,” said FDA Commissioner Martin A. Makary, M.D, M.P.H. In addition ...

The U.S. Food and Drug Administration (FDA) announced Tuesday that it will increase unannounced inspections at foreign manufacturing plants that produce food and drugs for U.S. consumption.

More than 20 of the agency’s roughly 60 travel staff will be reinstated, according to two FDA staffers notified of the plan this week, who spoke on condition of anonymity to discuss confidential ...